Colin Lyness, MD
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $450 of the $638 with a category attached, or 70.6%. Biogen accounts for 70.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $216, more than ten times the $15 reported in 2020. That places this record below the midpoint for neurology clinicians in ID, where the typical reported total is $1,243.
Across 12 payments — averaging $53.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$450
- AbbVie$61
- Johnson & Johnson$24
- Acadia Pharmaceuticals Inc$23
- Genentech USA, Inc.$19
- Bristol Myers Squibb$19
- plus $42 from 3 others
What the payments were for
- Consulting fees$45071%
- Food & beverage$18829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 3 | $450 |
| AbbVie | 2 | $61 |
| Johnson & Johnson | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Boston Scientific | 1 | $15 |
| Amgen | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$450
How this compares
$638 in reported general payments places this provider in the 35th percentile of 59 neurology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 11 | $111,424 |
| NeuproRotigotine | 11 | $9,392 |
| Pyridostigmine Bromide | 36 | $7,805 |
| Oxcarbazepine | 20 | $3,976 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 98 | $2,387 |
| Pregabalin | 19 | $2,297 |
| Dimethyl Fumarate | 15 | $2,290 |
| Carbamazepine ErCarbamazepine | 13 | $2,275 |
| Sumatriptan Succinate | 28 | $2,234 |
| Levetiracetam | 45 | $2,181 |
| Gabapentin | 67 | $2,173 |
| Baclofen | 38 | $1,264 |
| Duloxetine Hcl | 36 | $1,177 |
| Zonisamide | 17 | $1,016 |
| Memantine Hcl | 26 | $896 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boise
- Sergei KashirnyBoise$20K
- Anant WadhwaBoise$6K
- Jackie WhitesellBoise$2K
- Brittany LovascioBoise$2K
- Benjamin StewartBoise$2K
- Matthew TechyBoise$2K
- Kelly BlockBoise$2K
- Thomas StrobelBoise$1K
- Lukas ClarkBoise$1K
- James WhitesideBoise$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.